The seasoned approach
The set-and-setting framework operationalized clinically. What good practice looks like across screening, preparation, supervision, integration, and harm reduction. The discipline that distinguishes therapeutic psychedelic use from recreational use.
Layer 1 — Screening — psychiatric and medical
Personal or family history of psychotic disorders (absolute or relative contraindication depending on severity and stability). Personal history of bipolar I (relative contraindication). Active suicidality (typically excluded). Significant cardiovascular disease, uncontrolled hypertension (relative contraindications, particularly for psilocybin and MDMA which produce BP/HR effects). Pregnancy. Active substance use disorder requiring assessment. Medication interactions (particularly serotonergic agents).
Layer 2 — Set — psychological preparation
Intentions exploration — what does the patient hope to address. Fears and concerns — psychoeducation about the experience, preparation for difficult content if it emerges. Building therapeutic alliance with whoever will be present during the session. Mental state assessment immediately before the session — depression, anxiety, sleep, recent life stressors. The patient should arrive with reasonable equanimity and informed clarity about the work.
Layer 3 — Setting — physical and relational
Quiet, comfortable, controlled environment. Two trained facilitators present throughout the session (MAPS protocol; many psilocybin programs use single facilitator). Curated music, comfortable rest position, eye shades for inward focus. Safety throughout — no interruptions, accessible bathroom, snacks available afterward. The trusted presence of trained facilitators is part of the therapeutic frame, not background.
Layer 4 — The session itself
6–8 hour duration for psilocybin or MDMA. Patient lies down with eye shades; music plays. Facilitators sit nearby, available but not intrusive. Verbal interaction only when patient initiates. Difficult emotional content during the session is engaged with supportive presence rather than redirected. The facilitator's job is supportive presence and safety, not active interpretation during the session.
Layer 5 — Integration — the work after
First integration session within 1–3 days of dosing. Process the content of the experience, identify themes, connect to ongoing life. Subsequent sessions weekly for several weeks. The integration phase is where the acute experience becomes durable change — the neuroplastic window is open and the work of consolidating new patterns is the central therapeutic activity.
Layer 6 — Medication and lifestyle integration
Antidepressant taper before psilocybin (typically 2–4 weeks); resumption decisions after based on response. Coordinate with prescribing clinician. Lifestyle factors during integration — exercise, sleep, social engagement, limited alcohol — support the durability of change.
Special situations
- Patient pursuing psychedelics outside clinical structures: Harm-reduction conversation. Screen for psychiatric and medical contraindications. Discuss medication interactions. Recommend trusted setting and companion. Encourage integration work afterward (psychotherapy if available). Maintain clinical relationship — do not abandon. The patient who feels supported is more likely to seek help if difficulties emerge.
- Family history of psychosis but stable patient: Higher threshold for psychedelic recommendation. Lower-dose protocols, more conservative approach. Ketamine may be safer alternative for rapid-plasticity intervention given lower psychotomimetic concern.
- Patient on chronic SSRI considering psilocybin trial: Taper plan with prescribing clinician — typically 2–4 weeks off SSRI before session. Bridge with non-serotonergic agents if needed. Decision about resumption based on response and integration. The taper requires careful clinical management.
- Patient with prior difficult psychedelic experience: Detailed exploration of what happened — was it a "bad trip" with lasting impact, or simply a difficult experience that resolved. PTSD-like symptoms following prior psychedelic experience (HPPD, persistent dissociation) is a relative contraindication. Many patients with prior difficult experiences can have successful subsequent therapeutic experiences with proper preparation.
Generally avoid
- Psychedelic recommendation without psychiatric and medical screening — patients with relevant history (psychosis, bipolar, certain cardiovascular conditions) carry elevated risk.
- Unsupervised high-dose use in psychiatrically vulnerable patients — even in jurisdictions where access is legal, the structured supervision matters substantially for safety and outcome.
- Treating psychedelics as standalone interventions — the integration psychotherapy and lifestyle work are central to durable change, not optional add-ons.
- Abandoning patients who pursue psychedelics outside clinical structures — the harm-reduction posture preserves the clinical relationship and reduces actual harm; moralizing about the choice does the opposite.
The chief-resident note: The set-and-setting framework is the clinical discipline that distinguishes therapeutic psychedelic use from recreational use, and that distinguishes successful clinical programs from unsuccessful ones. The same drug at the same dose produces different outcomes depending on the surrounding clinical infrastructure. Build the practice that supports the work — proper screening, structured preparation, quality supervision, robust integration. Where you cannot provide this directly, refer to programs that can. The harm-reduction posture toward patients pursuing access outside clinical structures preserves the clinical relationship and the patient's safety.
The set-and-setting framework, originally articulated by Leary, Metzner, and others, has become the operational discipline of clinical psychedelic medicine. Set refers to the patient's psychological state — intentions, expectations, current mood, recent life context, therapeutic readiness. Setting refers to the immediate environment — physical comfort, relational support, freedom from interruption, the trained facilitators whose presence shapes the experience. The integration phase that follows is the third element that converts the acute experience into durable clinical change. The framework operationalizes the recognition that the same pharmacological agent at the same dose produces different therapeutic outcomes depending on the surrounding clinical infrastructure.
Screening is the first clinical discipline. Personal or family history of psychotic disorders represents a relative-to-absolute contraindication depending on severity and stability — psychedelics in vulnerable individuals can precipitate prolonged psychotic episodes. Bipolar I disorder is a relative contraindication; psychedelics can precipitate manic episodes. Active suicidality is typically excluded from trial protocols. Significant cardiovascular disease, uncontrolled hypertension, and certain medical conditions are contraindications particularly for psilocybin and MDMA, which produce BP/HR effects. Medication interactions are reviewed in detail — particularly serotonergic agents, which require taper before serotonergic psychedelic treatment.
Preparation work builds the set. 2–4 sessions before dosing typically address: intentions (what does the patient hope to engage), fears and concerns (psychoeducation about the experience, normalization of difficult content), therapeutic alliance with whoever will be present during the session, and clarification of the integration plan. The patient should approach the session with informed clarity rather than excessive expectation in either direction. The preparation work is therapeutic in its own right; many patients report that the preparation itself produces clinical benefit before the dosing session.
The setting infrastructure matters substantially. Quiet, comfortable, controlled environment without interruptions. Two trained facilitators present throughout (MAPS protocol; some programs use single facilitator). Curated music typically with arc structure across the 6–8 hour session. Eye shades and reclined position to support inward focus. The facilitators' role is supportive presence and safety monitoring rather than active interpretation during the session. The training and orientation of facilitators is one of the largest variables in outcome.
Integration psychotherapy is where durable change consolidates. The first integration session within 1–3 days of dosing addresses the content of the experience — what happened, what emerged, what patterns or insights were revealed. Subsequent weekly sessions for 4–8 weeks support the integration of the experience into ongoing life — behavioral changes, relationship adjustments, work or life decisions that flow from the insights. The integration phase is the work that produces durable clinical change; without it, the acute experience may produce temporary improvement that does not sustain.
The harm-reduction posture matters for the broader patient population. Many patients pursue psychedelics outside clinical structures — through state-level supervised programs, international access, underground use, or recreational contexts. The clinical posture that supports these patients without abandoning them — informed harm-reduction conversation, screening for contraindications, medication review, encouragement of integration work, continued clinical relationship — produces better outcomes than the moralizing posture that pushes patients away from clinical care. The discipline is to engage with the realities of psychedelic use in 2026 — both clinical and non-clinical — with the clinical infrastructure that maximizes benefit and reduces harm.